Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhopressa Post-SLT in Primary Open-Angle Glaucoma or Ocular Hypertension
NCT06865144Phase 4Active, not recruiting
- Sponsor
- East Coast Institute for Research
- Start
- Jun 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of netarsudil in primary open-angle glaucoma (POAG), ocular hypertension, sponsored by East Coast Institute for Research. Started Jun 2025; status: active, not recruiting.
02
Drugs
netarsudil
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT06865144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06865144.